EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.
Chen ZY, Zhong WZ, Zhang XC, Su J, Yang XN, Chen ZH, Yang JJ, Zhou Q, Yan HH, An SJ, Chen HJ, Jiang BY, Mok TS, Wu YL.
Chen ZY, et al. Among authors: su j.
Oncologist. 2012;17(7):978-85. doi: 10.1634/theoncologist.2011-0385. Epub 2012 Jun 6.
Oncologist. 2012.
PMID: 22673630
Free PMC article.